NCT03261284

D-dimer to Improve Anticoagulation Outcome During ECMO loNg-term supporteD

D-dimer to Improve Anticoagulation Management in Adult Patients Supported With Extracorporeal Membrane Oxygenation: a Prospective Cohort Study

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 300 (estimated)
• Sponsor: Wuhan Asia Heart Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This was a prospective, cohort study.

Detailed description

Adult Patients receiving ECMO surpport in Wuhan Asia Heart Hospital were enrolled by cohort. Unfractionated heparin was used for Anticoagulation therapy, APTT or Anti-Xa activity is monitored for dose adjustment. Meanwhile, D-dimer is mornitored. If D-dimer levels continue to rise (\>1.5 times previous result ), increase the dose of heparin to reach the upper limit of the treatment target; If the D-dimer levels is stable (\<1.5 times previous result ) or is decreasing, the anticoagulation dose is maintained at current level (no active bleeding) or decreased (active bleeding). All patients were followed up The occurrence of endpoints during in-hospital and 30 days after discharge, including bleeding events, thrombotic events and all-cause deaths were recorded.

Conditions

• Extracorporeal Membrane Oxygenation Complication
• Thrombosis
• Hemorrhage
• Heparin Overdose

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	D-dimer-guided adjustment stratege	D-dimer-guided adjustment stratege
DIAGNOSTIC_TEST	Thepeautic-heparin therapy	0.3-0.7U/ml of anti-Xa activity or APTT 1.5-2.5 times of control

Timeline

• Start date: 2019-03-01
• Primary completion: 2023-12-01
• Completion: 2023-12-30
• First posted: 2017-08-24
• Last updated: 2023-04-18

Locations

1 site across 1 country: China